Immatics (IMTX) Non-Current Deffered Revenue (2019 - 2025)
Immatics' (IMTX) quarterly Non-Current Deffered Revenue came in at $21.6 million in Q4 2025, down 40.88% year-on-year from $36.5 million in Q4 2024, and down 40.88% quarter-over-quarter from $36.5 million in Q4 2024.
Immatics (IMTX) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Immatics has disclosed Non-Current Deffered Revenue across 7 years of filings, most recently posting $21.6 million for Q4 2025.
- Non-Current Deffered Revenue for Q4 2025 came in at $21.6 million, down 40.88% year-over-year; the trailing twelve-month figure through Dec 2025 was $21.6 million (down 40.88% YoY), and the FY2025 annual result was $20.9 million, down 42.62% from the prior year.
- Non-Current Deffered Revenue came in at $21.6 million for Q4 2025 at Immatics, down from $36.5 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $124.3 million in Q4 2023 to a low of $21.6 million in Q4 2025.
- The 5-year median for Non-Current Deffered Revenue is $55.2 million (2021), against an average of $63.0 million.
- Across the five-year window, Non-Current Deffered Revenue surged 60.82% in 2023 and plunged 70.63% in 2024, its largest moves.
- Immatics' Non-Current Deffered Revenue stood at $55.2 million in 2021, then jumped by 40.1% to $77.3 million in 2022, then soared by 60.82% to $124.3 million in 2023, then sank by 70.63% to $36.5 million in 2024, then plunged by 40.88% to $21.6 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $21.6 million (Q4 2025), $36.5 million (Q4 2024), and $124.3 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | 21.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.58 Mn |
| Dec 31, 2024 | 36.50 Mn |
| Dec 31, 2023 | 124.30 Mn |
| Dec 31, 2022 | 77.29 Mn |
| Dec 31, 2021 | 55.17 Mn |
| Dec 31, 2020 | 101.91 Mn |
| Dec 31, 2019 | 94.61 Mn |